<DOC>
	<DOCNO>NCT01882504</DOCNO>
	<brief_summary>The study evaluate safety biologic activity gevokizumab subject acute inflammatory phase pyoderma gangrenosum .</brief_summary>
	<brief_title>Proof Concept Study Gevokizumab Treatment Pyoderma Gangrenosum</brief_title>
	<detailed_description />
	<mesh_term>Pyoderma Gangrenosum</mesh_term>
	<mesh_term>Pyoderma</mesh_term>
	<criteria>An establish diagnosis pyoderma gangrenosum Currently experience inflammatory episode pyoderma gangrenosum Contraceptive measure adequate prevent pregnancy study Clinical evidence acutely infected pyoderma gangrenosum History allergic anaphylactic reaction monoclonal antibody History recurrent chronic systemic infection Female subject pregnant , plan become pregnant , recently deliver , breastfeed Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Pyoderma Gangrenosum</keyword>
	<keyword>Classic Pyoderma Gangrenosum</keyword>
	<keyword>Atypical Pyoderma Gangrenosum</keyword>
	<keyword>Peristomal Pyoderma Gangrenosum</keyword>
</DOC>